- Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
- Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates
- Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events
- Editas Medicine to Participate in Upcoming Investor Conferences
- Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference
- Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9
- Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar
- Editas Medicine Announces Third Quarter 2023 Results and Business Updates
- Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar
More ▼
Key statistics
On Friday, Editas Medicine Inc (EDIT:NSQ) closed at 5.32, 4.11% above its 52-week low of 5.11, set on Apr 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.25 |
---|---|
High | 5.40 |
Low | 5.13 |
Bid | 5.35 |
Offer | 5.48 |
Previous close | 5.22 |
Average volume | 1.72m |
---|---|
Shares outstanding | 82.23m |
Free float | 81.97m |
P/E (TTM) | -- |
Market cap | 429.27m USD |
EPS (TTM) | -2.06 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 21:00 BST.
More ▼